Fresh off its obesity drug success, Eli Lilly last month agreed to acquire Centessa Pharmaceuticals, a clinical-stage biotech treating sleep disorders, for up to $7.8 billion.
Why it matters: Centessa is developing orexin agonists, a drug class investors see as potentially having broad applications across neurological and metabolic conditions, similar to GLP-1s.
